Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.
about
The Role of Immunotherapy in Multiple MyelomaImmunotherapy strategies for multiple myeloma: the present and the futureDendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to ClinicNovel therapeutic strategies for multiple myelomaCross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cellsNew strategies in the treatment of multiple myeloma.Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.Advances in the study of HLA-restricted epitope vaccines.A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patientsHeteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.Profile of elotuzumab and its potential in the treatment of multiple myelomaLow-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapyMultiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancerLenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3(+)CD8(+) T cells against Various Solid Tumors.Immunotherapy for multiple myeloma.T cell-based targeted immunotherapies for patients with multiple myeloma.Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.Vision Statement for Multiple Myeloma: Future Directions.The Unfolded Protein Response in Homeostasis and Modulation of Mammalian Immune Cells.Current treatment options of T cell-associated immunotherapy in multiple myeloma.YM-175 induces apoptosis of human native monocyte-lineage cells via inhibition of prenylation.Development of Peptide Vaccines in Dengue.Dendritic cell cancer vaccines: from the bench to the bedside.Progress and Paradigms in Multiple Myeloma.Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy.
P2860
Q26771144-6340F9C6-7015-4918-A516-1D8C5DAF0417Q27021939-824CA86F-D1FA-49C2-A110-8F470FB56DBEQ27023621-8A3898E0-DFE6-46EE-9DBD-BB4AF2848E4BQ28081590-745124A8-58A6-43BC-91CF-830A2666DCB7Q33613138-A40BCED4-E87A-4AE1-ABF6-69BDC3E3D901Q33958520-A21B02F0-256E-4385-A05B-4226867DD6BBQ34052565-7E76DDAF-0C9F-4BAA-B909-154A9E29C545Q34170130-3F789F3D-B18B-4C0E-99F5-8163DB95F966Q34543937-13E938ED-4DF4-4D9F-88F6-921F5F0056D5Q35166674-3B03D723-B1BD-404B-8A64-B221A9F03A79Q35628678-5673569E-18FC-4F57-8B68-25A8FB2576D4Q35713347-1FFC911D-8DC4-4F4C-A330-7CF975674509Q36169794-39B447CE-C659-47B4-A2CF-1BA60AC23F45Q36803441-E98BD692-A0C2-40FF-A053-FD300C28123CQ37275289-0DC62507-DB55-454A-8DD0-2401CD1D575BQ38177879-2D39A19C-B262-464D-AED5-F5B556E9E980Q38246639-883D856D-AA40-4022-A753-A804FAF2B762Q38286381-A977AE65-5997-4816-9BA7-9D227E54A798Q38671390-FDD51808-8C0F-48DC-8B17-3A115AC4F7F3Q38792725-F625D540-B415-4ED7-A20F-81177658B8E6Q38815409-885D0050-C6C2-465D-AABF-88725F72D424Q38818892-A53A295D-4B98-4AAC-B729-DC9DD7CCEC8EQ39102170-28CC6994-67A7-4DF5-870D-23763FAD7B57Q39264030-EE01A8E4-0104-4966-ADD2-B50D8F9A58CCQ40038715-8321E81B-45FA-4141-AEF5-7B6522F41BBFQ42979673-E9E8094A-AB14-4EE4-B6EE-CB99D974F564Q44694137-FC9CFC44-F082-407B-87D2-B73D8156A06FQ47580433-5575708B-3380-4B4D-867A-083E6E0678E6Q47829053-2803A21B-D4DD-4BCD-A29A-C44052F5B29BQ52327450-D7C8CC43-D151-4BC9-A5C3-779F23350618
P2860
Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Myeloma-specific multiple pept ...... d other plasma cell disorders.
@en
Myeloma-specific multiple pept ...... d other plasma cell disorders.
@nl
type
label
Myeloma-specific multiple pept ...... d other plasma cell disorders.
@en
Myeloma-specific multiple pept ...... d other plasma cell disorders.
@nl
prefLabel
Myeloma-specific multiple pept ...... d other plasma cell disorders.
@en
Myeloma-specific multiple pept ...... d other plasma cell disorders.
@nl
P2093
P2860
P1476
Myeloma-specific multiple pept ...... d other plasma cell disorders.
@en
P2093
John Daley
Jooeun Bae
Naoya Mimura
Nikhil C Munshi
Robert Smith
Yu-Tzu Tai
P2860
P304
P356
10.1158/1078-0432.CCR-11-2776
P407
P577
2012-07-02T00:00:00Z